Innovations • Global Impact • In The News • Our People

AAHI's Immune-Enhancing Platform Technologies Support Diagnosis and Prevention of Neglected Tropical Disease

AAHI scientists take a pragmatic and creative approach to product development to create affordable and temperature stable diagnostic tests and life-saving vaccines and therapeutics that are meaningfully accessible and available to people in rural, remote, and low-resource parts of the world.


The latest scientific breakthroughs at AAHI.

Make your products accessible to those who need them most. Collaborate with AAHI.



Collaboration across communities. Explore AAHI's different areas of impact.

Seattle, USA

AAHI is awarded $9.9M to develop a nasal spray influenza RNA vaccine through Phase 1 clinical trials

Respiratory viruses pose a unique biological threat to global health. In collaboration with the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), AAHI scientists are developing a prototype intranasal influenza RNA vaccine on AAHI's self-amplifying RNA platform. The vaccine candidate targets both pandemic A(H5N1) and A(H7N9) influenza pathogens and can be easily administered as a nasal spray, to induce a mucosal immune response that may both prevent early infection and curtail viral transmission.

Halifax, Canada

Inventprise commences first-in-human clinical trials of its pneumococcal vaccine candidate, with manufacturing support from AAHI

The biotechnology company Inventprise, based in Redmond, WA, recently announced that its 25-valent pneumococcal conjugate vaccine (IVT PCV-25), developed in collaboration with PATH and with funding support from the Bill & Melinda Gates Foundation, entered the clinic. The pneumococcus bacterium is responsible for an estimated 300,000 deaths per year in children under the age of five. AAHI's GMP manufacturing team prepared the Inventprise vaccine candidate for clinical trials - filling vials with the vaccine and finishing the process of packaging the vaccine for use. 

Help us make impossible vaccines possible.


By Gail Dutton


After much deliberation of a long-term COVID-19 vaccination strategy, the Food and Drug Administration's (FDA) vaccine advisory committee concluded everyone should get an annual COVID vaccine that is tailored to the latest variants. Yet there remains skepticism as to whether the omicron-specific booster shots offer improvement over the original vaccine and whether annual shots are sufficient for the most vulnerable populations as transmission of the virus continues causing further mutations. Dr. Corey Casper, CEO, has shared the uniting views of the FDA that next-generation vaccine development is necessary to stop chasing emergent variants and provide long-term protection.


Collaboration across communities. Explore our different areas of impact.

Openings and Opportunities

Biotech Manufacturing

The Quality Control Associate I/II will be responsible for performing analytical tests, gathering and assessing data from those tests, and writing documentation and reports. The candidate will work in quality control laboratories in a GMP Manufacturing setting.


The Associate / Staff Scientist will be responsible for managing and executing formulation development
and stability studies, including collecting, analyzing, reviewing, and reporting bulk antigen and drug
product characterization for multiple projects.


The Associate / Staff Scientist will be responsible for performing assay development, optimizations and
validations, preparation of blood specimens for ex vivo assays under BSL 2 conditions, performing a
variety of immunological assays, and assisting in drafting manuscripts.


The Senior Scientist joining our RNA vaccine team will be responsible for broadening the applications of
AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets.

Learn more about our formulation technology

We partner with biotech leaders to develop vaccines and more.

Synthetic TLR4 ligand in squalene nanoemulsion

Synthetic TLR4 ligand in QS- 21 containing liposome

Synthetic TLR4 ligand in aqueous formulation

Dual agonist containing both TLR4 and TLR7/8 ligands

2nd-Gen synthetic TLR4 ligand
in squalene nanoemulsion

2nd-Gen synthetic TLR4 ligand
in QS-21 containing liposome

2nd-Gen synthetic TLR4 ligand
in aqueous formulation

Alum nanoparticle formulation, customized particle size

Synthetic TLR7/8 ligand in
squalene nanoemulsion

Synthetic TLR7/8 ligand
adsorbed to aluminum

Synthetic TLR7/8 ligand in
aqueous formulation

Nanostructured lipid carrier

See how our formulations are being used.

Follow AAHI

Sign up to stay in touch!

Get the latest news and updates in your inbox every month and learn more about how our scientists are developing equitably accessible vaccines and therapeutics for people who most need them.